Efficacy and Safety Assessments of a Peritoneal Dialysis Solution Containing Glucose, Xylitol, and L-Carnitine in CAPD
Status:
Recruiting
Trial end date:
2022-07-30
Target enrollment:
Participant gender:
Summary
Prospective, randomized, controlled clinical trial. The aim is to compare the effects of the
peritoneal dialysis solution IPX15, containing glucose (0.5%), xylitol (1.5%) and L-carnitine
(0.02%) as osmotic agents (comparable to the standard 2.5% glucose PD solution), for the
nocturnal exchange with the PD solution IPX07, containing glucose (0.5%), xylitol (0.7%) and
L-carnitine (0.02%) as osmotic agents (comparable to the standard 1.5% glucose PD solution),
for the diurnal (short dwell) exchanges. Planned total recruitment is 40 patients with stable
end-stage renal disease (ESRD) treated by continuous ambulatory peritoneal dialysis (CAPD).
Treatment duration will be 4 weeks plus a 4 weeks safety follow up with no treatment.